Loading
A phase 2 trial of Adebrelimab, Etoposide, Carboplatin and Cisplatin in advanced solid tumours, run by Shanghai Hengrui Pharmaceutical Co., Ltd., now recruiting.
A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors is a phase 2 interventional study registered as NCT07268040 by Shanghai Hengrui Pharmaceutical Co., Ltd., with 400 participants planned, started 2025-12-23 and due to reach its primary completion in 2028-12. Interventions recorded: SHR-7787 Injection, SHR-1316 Injection, SHR-4849 Injection, Etoposide injection, Carboplatin injection and Cisplatin injection.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin, Carboplatin and the tag pipeline.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin, Carboplatin and the tag pipeline.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin, Carboplatin and the tag pipeline.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Cisplatin, Carboplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.